PHC398 Approved by US EPA: PHC279 submitted to EPA

RNS Number : 0288Q

Plant Health Care PLC

15 June 2020

 

RNS

15 June 2020

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

PHC398 Approved by US EPA and   PHC279 submitted to US EPA

Plant Health Care^®, a leading provider of novel patent-protected biological products to global agriculture markets, is pleased to announce the US EPA has approved its application for the novel peptide product, PHC398.   

Highlights:

-  PHC398 is the first active ingredient from Plant Health Care's PREtec technology platform approved for registration anywhere in the world.

-  The registration of PHC398 makes the process of registering future PREtec products in the US quicker and cheaper.

-  The high-performance variant of PHC398, known as PHC279, was submitted for EPA approval on May 14th, 2020 and is currently expected to be approved in the second half of 2021.

Plant Health Care's PREtec peptides represent a novel class of technology to stimulate the plant to defend itself. Derived from natural proteins, PREtec is an environmentally friendly approach to protecting crops and increasing yields, and is compatible with mainstream agricultural practice. Whether applied as a seed treatment or foliar spray, PREtec peptides promote plant health, suppress disease and soil nematodes, and increase yield. PREtec may allow farmers to reduce applications of less safe chemical fungicides and to achieve better control of damaging plant diseases.

Plant Health Care has now submitted PHC279 for approval by the US EPA for use on a wide range of row crops (such as corn and soybeans) and fruit and vegetable crops; this will be the first of a series of peptides the Company intends to commercialize over the next two to three years.

Chris Richards, CEO of Plant Health Care, said "We are very pleased to have achieved this first registration of a PREtec peptide. The EPA's positive review on PHC398 greatly increases the probability that future peptides from the PREtec platform will be registered quickly and at low cost.  The first commercial product in line for registration is PHC279 which has generated strong results from testing in 2019 in the US and Brazil. We are excited about the potential for products based on our PREtec peptides, which are targeting markets valued at $5 billion."

For further information, please contact:

Plant Health Care plc

Chris Richards, CEO  Tel: [phone]

Arden Partners plc - Nomad & Broker

John Llewellyn-Lloyd / Dan Gee-Summons  Tel: [phone]

Company website: www.planthealthcare.com

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

END

 

 

REAKZGMVNKZGGZM